Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Apatinib in Nasopharyngeal Carcinoma with Residual EBV DNA
NCT02874651Phase 2Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Oct 2016; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02874651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874651.